Skip to main content

Table 4 Cost-Effectiveness analysis results

From: Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database

Ā 

GEM-E

GEM

(nā€‰=ā€‰1,331)

(nā€‰=ā€‰2,936)

Effectiveness

325.6 days

305.6 days

(Overall mean survival time)

(0.894 year)

(0.839 year)

Incremental Effectiveness

20 days

-

(0.055 year)

Costa

USD 23,819.51

USD 19,927.98

Incremental Cost

USD 3,891.53

-

Incremental Cost-Effectiveness Ratio (ICER)

USD 70,755.06/year

-

  1. Abbreviation: GEM Gemcitabine, GEM-E Gemcitabineā€‰+ā€‰Erlotinib
  2. aAverage 2013 exchange rate: one US dollar (USD)ā€‰=ā€‰1,113.85 Korea Won (KRW)